MétaCan
Menu
← Back to cohort
Record W2011917645 · doi:10.5489/cuaj.11282

Helping patients with voiding dysfunction: What are our current options?

2011· article· en· W2011917645 on OpenAlexvenueno aff
Kurt McCammon

Bibliographic record

VenueCanadian Urological Association Journal · 2011
Typearticle
Languageen
FieldMedicine
TopicPelvic floor disorders treatments
Canadian institutionsnot available
Fundersnot available
KeywordsCurrent (fluid)PsychologyMedicineIntensive care medicineEngineeringElectrical engineering

Abstract

fetched live from OpenAlex

Patients with voiding dysfunction, such as overactive bladder (OAB) syndrome and non-obstructive retention, who have failed conservative treatment are candidates for sacral nerve stimulation (SNS). Sacral nerve stimulation was originally described by Tanagho and Schmidt.1 Medtronic received United States Food and Drug Administration (FDA) approval for Interstim in July 1998 for urge incontinence. To proceed with full implant, patients were initially tested with a percutaneous nerve evaluation (PNE). The percutaneous permanent tined lead (PPTL) was released in 2002 and is now the most commonly used procedure performed prior to a patient receiving a permanent implant.2 The advantage of the PPTL over PNE is higher implantation rates 88% versus 46%.3 Richard and colleagues used an interesting approach looking at the PNE as an adjunct to the PPTL and the implanted pulse generator implant. They performed a retrospective chart review of 106 patients who underwent 116 PNEs. Of these 116 patients, 62 (53%) had a successful PNE. Of these successful cases, 57 (92%) went on to an implant. Using the PNE allowed them to pre-select patients for PPTL, which increased their overall success.4 The authors address noteworthy considerations in their approach to SNS. The most worthwhile is the use of a 60% goal for symptom improvement compared to the standard 50%, which was an initial arbitrary goal. Some may argue we should consider an even higher improvement rate, possibly 70%. The authors astutely point out that the placebo success rate for anticholinergics can be as high as 60%, clearly explaining why some patients do not improve even after a full implant. Considering the significant expense of the product, elimination of the placebo effect would decrease cost, improve efficacy and prevent unnecessary procedures. Additionally, the authors discuss the prospect that using this three-stage approach may reduce the overall cost of SNS, as the cost of the PPTL staged approach is significantly less than a PNE. This may reduce the general cost to society; however, with the lower success rate of PNE, one cannot help but wonder if treatment is being withheld from some patients who are suffering. The authors should be commended for reviewing their data and trying to identify cost-efficient and more efficacious methods of providing care for their patients. A large multi-centre trial evaluating cost and efficacy would be optimal, but unfortunately improbable. As new treatment modalities enter the market, we must continue to assume the responsibility to weigh their costs and benefits to achieve the best outcomes for the greatest number of patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.020
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.010
Threshold uncertainty score0.032

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.020
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0020.001
Science and technology studies0.0030.003
Scholarly communication0.0060.013
Open science0.0030.003
Research integrity0.0080.014
Insufficient payload (model declined to judge)0.0100.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.229
Teacher spread0.202 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Urological Association Journal→Same topicPelvic floor disorders treatments→French-language works237,207→